Delayed percutaneous transluminal coronary angioplasty after acute myocardial infarction.
The value of delayed percutaneous transluminal coronary angioplasty (> 12 h from admission or after thrombolytic therapy) following acute myocardial infarction is controversial. We compared the short- and long-term prognosis of 1940 consecutive patients after acute myocardial infarction, of whom 188 underwent delayed percutaneous transluminal coronary angioplasty. Delayed percutaneous transluminal coronary angioplasty was more frequently done in patients treated with thrombolysis (12%) than among patients excluded from thrombolytic therapy (8%; P=0.005). Patients in the delayed percutaneous transluminal coronary angioplasty group were younger, included more men and smokers and had less in-hospital complications in comparison to patients who did not undergo delayed percutaneous transluminal coronary angioplasty. The crude 30-day and 1-year mortality rates were 3 and 6% among patients who underwent percutaneous transluminal coronary angioplasty vs. 14 and 21% (P<0.01 for each) among those without percutaneous transluminal coronary angioplasty, respectively. After multivariate analysis adjusted for confounding factors, delayed percutaneous transluminal coronary angioplasty was associated with 65 (RR=0.35; 90% CI 0.14-0.88) and 50% (RR=0.50; 90% CI 0.27-0.92) mortality risk reduction after 30 days and 1 year, respectively. In conclusion, delayed percutaneous transluminal coronary angioplasty applied to selected post-myocardial infarction patients upon clinical indication is safe and beneficial for the treatment of acute myocardial infarction in the community.